Drug intelligence / Profile preview

CUG279

Development stage: Preclinical
Lead developer: Cugene
Modality: Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

CUG279 (also known as VitoKine 2) is a novel tumor-infiltrating lymphocyte (TIL)-targeting, tumor-activatable interleukin-2 (IL-2) replacement therapy. It is being developed by Cugene for the treatment of solid tumors. The drug acts as an immunotherapy and antineoplastic agent by stimulating T lymphocytes through IL-2 receptor activation. Its design aims to enhance anti-tumor immune responses while minimizing systemic toxicity typically associated with traditional IL-2 therapies. As of June 2024, CUG279 remains in preclinical development for solid tumors[1][2].

Other names: CUG 279CUG279CUG-279VitoKine-2VitoKine2VitoKine 2

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on CUG279.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUG279.

Explore the full profile